Trxade Group, INC.: management transactions · United States · SEC (Form 4)

About Trxade Group, INC.

TRxADE GROUP, INC. (historical ticker: MEDS) is a U.S.-based company that was listed on the NASDAQ market in the United States. The business originally built its identity around a B2B pharmaceutical marketplace designed to improve drug-pricing transparency and support independent pharmacies in sourcing products more efficiently. SEC filings and company communications show that the enterprise was founded in 2010 and has long been associated with Tampa, Florida, with its core activity focused on the U.S. healthcare and pharmaceutical supply chain. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1382574/000107878218000252/f10k123117_10k.htm?utm_source=openai)) Operationally, TRxADE historically combined several complementary platforms: the Trxade B2B trading marketplace, Integra Pharma Solutions as a licensed pharmaceutical wholesaler, Bonum Health for telehealth services, and DelivMeds for pharmacy-based or mail-order delivery capabilities. The strategic idea was to cover a broader portion of the healthcare value chain, from price discovery and procurement through to fulfillment and patient access. Earlier corporate materials emphasized a nationwide U.S. footprint and a sizeable network of pharmacy members, underscoring the company’s niche positioning among independent pharmacies and healthcare buyers seeking sourcing efficiency. ([nasdaq.com](https://www.nasdaq.com/press-release/trxade-group-inc.-reports-2019-results-2020-03-30?utm_source=openai)) From a competitive standpoint, TRxADE operates in a fragmented but highly competitive landscape spanning pharmaceutical distribution, digital procurement, telehealth, and last-mile pharmacy delivery. Its differentiation has historically been based less on scale and more on specialization: helping buyers and sellers access better visibility on pricing, improve procurement economics, and serve a mix of brand, generic, and non-drug product demand. SEC filings filed in 2024 confirm that the company’s primary operations were centered on Integra Pharma Solutions, described as a licensed wholesaler selling to government entities, hospitals, clinics, and independent pharmacies across the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1382574/000149315224037953/ex99-1.htm?utm_source=openai)) A key recent development is the company’s strategic reset. In 2024, the company announced a name change to Scienture Holdings, Inc., with trading under a new NASDAQ symbol, SCNX, beginning September 23, 2024. The same disclosures indicate that the business had shifted its primary operating focus toward Integra Pharma Solutions following the sale of substantially all of the assets of a wholly owned subsidiary. For investors tracking SEC Form 4 insider transactions, this matters because the legacy MEDS story is now better understood as a transitioning specialty-pharma and distribution platform rather than a pure marketplace technology company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1382574/000149315224037953/ex99-1.htm?utm_source=openai))